ReviewInternational journal of molecular and cellular medicine2025
Trace Amine-associated Receptor 1: Role in the Implementation of Neuroprotective Signaling Pathways.
Review in International journal of molecular and cellular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trace amine-associated receptor 1 (TAAR1) is a classical representative of G-protein coupled receptors (GPCRs). It is widely distributed in the mammalian brain, potentially plays an important role in modulating neurotransmitter functions and may regulate synaptic transmission and neuronal activity. Studies on TAAR1 signaling pathways were reviewed to identify the potential of TAAR1 as a novel target for neuroprotection and neurorepair. TAAR1 realizes effects through binding to the G-protein subunits Gas or Ga13. The target of Gas is PKA and the target of Ga13 is RhoA. Among the RhoA-mediated effects of TAAR1, effects on MAPK/ERK pathway kinases, AMPA and NMDA glutamate receptors and CREB factor have been investigated. RhoA-mediated effects include effects on the internalization of DAT and EAAT3, neuronal transporters of dopamine and glutamate. A G-protein independent pathway is mediated by β-arrestin and is probably related to the formation of the TAAR1-D2R heterodimer. The modulatory effect of TAAR1 on neurotransmitter systems allows us to consider TAAR1 agonists as potential therapeutic agents for the treatment of neurodegenerative diseases and psychiatric disorders, as well as neuroprotectors in ischemic brain damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.